
Global R&D Pipeline
My Favorite
Hot Targets:
FPR2
Back
Total number of drugs
20
Phase II and later clinical stages
5%
Involving companies
17
Main therapeutic areas
Other Diseases
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Quin-C1 | Quin-C1 | Synthetic peptide | Other Diseases | N-formyl peptide receptor 2 stimulants | University of Illinois | University of Illinois | Preclinical | Quin-C1 | detail > | ||||||||||||
| FPR1/FPR2 Agonist(BMS) | FPR1/FPR2 Agonist(BMS) | Small molecule drug | Cardiovascular Diseases Respiratory Diseases | formyl peptide receptor 1 agonists N-formyl peptide receptor 2 stimulants | Bristol Myers Squibb Co. | Discovery | FPR1/FPR2 Agonist(BMS) | detail > | |||||||||||||
| F2Pal16 pepducins | F2Pal16 pepducins | Synthetic peptide | Infectious Diseases | N-formyl peptide receptor 2 modulators | University of Gothenburg | Preclinical | F2Pal16 pepducins | detail > | |||||||||||||
| F2Pal12 pepducins | F2Pal12 pepducins | Synthetic peptide | Infectious Diseases | N-formyl peptide receptor 2 modulators | University of Gothenburg | Preclinical | F2Pal12 pepducins | detail > | |||||||||||||
| F2Pal10 pepducins | F2Pal10 pepducins | Synthetic peptide | Infectious Diseases | N-formyl peptide receptor 2 modulators | University of Gothenburg | Preclinical | F2Pal10 pepducins | detail > | |||||||||||||
| ACT-389949 | ACT-389949 | Small molecule drug | Endocrinology and Metabolic Disease | N-formyl peptide receptor 2 stimulants | Johnson & Johnson | Pending | ACT-389949 | detail > | |||||||||||||
| BMS-986235 | BMS-986235 | Small molecule drug | Other Diseases | N-formyl peptide receptor 2 stimulants | Bristol Myers Squibb Co. | Phase 1 | BMS-986235 | detail > | |||||||||||||
| AMS-21 | AMS-21 | Small molecule drug | Other Diseases | N-formyl peptide receptor 2 stimulants | Università degli Studi di Brescia | Università degli Studi di Brescia | Discovery | AMS-21 | detail > | ||||||||||||
| WRW4 | WRW4 | Synthetic peptide | Endocrinology and Metabolic Disease | N-formyl peptide receptor 2 inhibitors | Shandong University | Shandong University | Preclinical | Preclinical | WRW4 | detail > | |||||||||||
| Tetrascorpin-1 | Tetrascorpin-1 | Peptides | Immune System Diseases Nervous System Diseases Other Diseases | N-formyl peptide receptor 2 stimulants | University of Campania Luigi Vanvitelli | University of Campania Luigi Vanvitelli | Preclinical | Tetrascorpin-1 | detail > |
Total 20 data
1
2


